Immunohistochemical studies have reported EGFR overexpression in 22–81% of NSCLC tumours depending on the antibody used and cut point that defines overexpression (Veale et al, 1987; Volm et al, 1993; Pfeiffer et al, 1996; Cornianu and Tudose, 1997; Pastorino et al, 1997; Rusch et al, 1997; Fontanini et al, 1998; Greatens et al, 1998; D'Amico et al, 1999; Fu et al, 1999; Cox et al, 2000; Ohsaki et al, 2000; Selvaggi et al, 2002; Hirsch et al, 2003; Kanematsu et al, 2003; Mukohara et al, 2003; Onn et al, 2003). The gene discussed is EGFR; the disease is neoplasm.